Amryt Pharma plc Holding(s) In Company
12 Outubro 2020 - 7:00AM
UK Regulatory
TIDMAMYT
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible)(i)
--------------------------------------------------------------------------------------------------------------------------------
1a. Identity of the issuer or the underlying
issuer of existing shares to which Amryt Pharma PLC
voting rights are attached(ii) : GB00BKLTQ412
-------------------------------------------------------------------- ----------------------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
--------------------------------------------------------------------------------------------------------------------------------
Non-UK issuer
--------------------------------------------------------------------------------------------------------- ---------------------
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
--------------------------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
--------------------------------------------------------------------------------------------------------- ---------------------
An acquisition or disposal of financial instruments X
--------------------------------------------------------------------------------------------------------- ---------------------
An event changing the breakdown of voting rights
--------------------------------------------------------------------------------------------------------- ---------------------
Other (please specify)(iii) :
--------------------------------------------------------------------------------------------------------- ---------------------
3. Details of person subject to the notification obligation(iv)
UBS Asset Management - O'Connor
Name UBS Group AG
City and country of registered office
(if applicable) Zürich, Switzerland
4. Full name of shareholder(s) (if different from 3.)(v)
--------------------------------------------------------------------------------------------------------------------------------
Name UBS O'Connor LLC
-------------------------------------------------------------------- ----------------------------------------------------------
City and country of registered office
(if applicable) Wilmington, USA
-------------------------------------------------------------------- ----------------------------------------------------------
5. Date on which the threshold was
crossed or reached(vi) : 7 October 2020
-------------------------------------------------------------------- ----------------------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 9 October 2020
-------------------------------------------------------------------- ----------------------------------------------------------
7. Total positions of person(s) subject to the notification obligation
--------------------------------------------------------------------------------------------------------------------------------
% of voting rights
through financial
% of voting rights instruments Total number
attached to shares (total of 8.B 1 Total of both of voting rights
(total of 8. A) + 8.B 2) in % (8.A + 8.B) of issuer(vii)
---------------------- -------------------- ---------------------- ----------------------------------- ---------------------
Resulting situation
on the date on
which threshold
was crossed or
reached - 6.12% 6.12% 162'801'593
---------------------- -------------------- ---------------------- ----------------------------------- ---------------------
Position of previous
notification (if
applicable) 2.60% 3.53% 6.13%
---------------------- -------------------- ---------------------- ----------------------------------- ---------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached(viii)
--------------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
--------------------------------------------------------------------------------------------------------------------------------
Class/type of
shares
ISIN code (if
possible) Number of voting rights(ix) % of voting rights
----------------------
Direct Indirect Indirect
(Art 9 of Directive (Art 10 of Directive Direct (Art 10 of Directive
2004/109/EC) 2004/109/EC) (Art 9 of Directive 2004/109/EC)
(DTR5.1) (DTR5.2.1) 2004/109/EC) (DTR5.1) (DTR5.2.1)
--------------------- -------------------- ---------------------- ----------------------------------- ---------------------
GB00BKLTQ412 - -
---------------------- -------------------- ---------------------- ----------------------------------- ---------------------
SUBTOTAL 8. A - -
---------------------- -------------------------------------------- ----------------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
--------------------------------------------------------------------------------------------------------------------------------
Number of voting
rights that may be
acquired if the instrument
Type of financial Expiration Exercise/ is
instrument date(x) Conversion Period(xi) exercised/converted. % of voting rights
---------------------- -------------------- ---------------------- ----------------------------------- ---------------------
US03217L1061 9'967'620 6.12%
---------------------- -------------------- ---------------------- ----------------------------------- ---------------------
SUBTOTAL 8. B 1 9'967'620 6.12%
---------------------- ----------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to Art.
13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
--------------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Physical or cash Number of % of voting rights
instrument date(x) Conversion settlement(xii) voting rights
Period (xi)
--------------------- --------------------- ---------------------- ---------------- ---------------------
SUBTOTAL 8.B.2
---------------- ---------------------
9. Information in relation to the person subject to the notification obligation
(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any
natural person or legal entity and does not control any other undertaking(s)
holding directly or indirectly an interest in the (underlying) issuer(xiii)
Full chain of controlled undertakings through which the voting rights
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity(xiv) (please add additional
rows as necessary) X
---------------------------------------------------------------------------------- -----------------------
% of voting rights
through financial
% of voting rights instruments if it Total of both if
if it equals or is equals or is higher it equals or is higher
higher than the notifiable than the notifiable than the notifiable
Name(xv) threshold threshold threshold
------------------------ ------------------------------ ------------------------ -----------------------
UBS Group AG
------------------------ ------------------------------ ------------------------ -----------------------
UBS AG
------------------------ ------------------------------ ------------------------ -----------------------
UBS Americas Holding
LLC
------------------------ ------------------------------ ------------------------ -----------------------
UBS Americas Inc
------------------------ ------------------------------ ------------------------ -----------------------
UBS Asset Management
(Americas) Inc
------------------------ ------------------------------ ------------------------ -----------------------
UBS O'Connor LLC - 6.12% 6.12%
------------------------ ------------------------------ ------------------------ -----------------------
10. In case of proxy voting, please identify:
-----------------------------------------------
Name of the proxy holder
---------------------------------------------
The number and % of voting rights held
---------------------------------------------
The date until which the voting rights
will be held
---------------------------------------------
11. Additional information(xvi)
-----------------------------------------------
Place of completion Opfikon, Switzerland
------------------- --------------------
Date of completion 09.10.2020
------------------- --------------------
(END) Dow Jones Newswires
October 12, 2020 06:00 ET (10:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
Notícias em tempo-real sobre Amryt Pharma Plc da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Amryt Pharma Plc
